College of Medicine, Hawler Medical University, Iraq.
J Immunotoxicol. 2012 Apr-Jun;9(2):168-72. doi: 10.3109/1547691X.2011.642419. Epub 2012 Apr 4.
The present study was performed to assess the immune response in women with human papilloma virus (HPV) DNA⁺ and DNA⁻ cervical lesions. Eighty women with cervical lesions (age range = 25-70 years) and 20 healthy individuals (control group) were enrolled in the study. Lesions were cytologically classified into four groups: ASC-US (20), CINI (30), CINII-III (16), and cervical carcinoma (14) prior to HPV DNA detection. Estimation of interleukin (IL)-10 and tumor necrosis factor (TNF)-α levels in cervical secretions and serum of the studied patients was performed utilizing ELISA. PCR screening kits were used to detect HPV DNA in cervical smears obtained from the studied cases with the different lesions. IL-10 levels in cervical secretions of HPV DNA⁺ were significantly greater than those from DNA⁻ patients (i.e., 88.73 vs 24.00 pg/ml) and from controls (i.e., 88.73 vs 8.27 pg/ml) and the levels were higher in DNA⁻ patients than in controls (i.e., 24.00 vs 8.27 pg/ml). In comparison, serum IL-10 levels in these patients did not significantly differ from control values (i.e., 13.69 vs 12.16 vs 9.99 pg/ml, respectively). TNFα levels in cervical secretions of the HPV DNA⁺ and DNA⁻ cases did not significantly differ from values for the controls (i.e., 12.18 vs 9.90 vs 7.90 pg/ml, respectively). Serum TNFα of these patients also did not differ significantly from controls (i.e., 11.59 vs 11.90 vs 10.83 pg/ml, respectively). The detected levels of IL-10 in cervical secretions of patients with HPV DNA⁺ lesions was significantly higher than in their sera, while secretion TNFα levels were nominally greater than sera values. Lastly, higher levels of IL-10 were observed in secretions of 10-14 (71.4%) patients who had progressive cervical lesions (HSIL and cervical cancer stages) who were HPV DNA⁺ than observed in 20 of 66 (30.0%) of DNA⁻ patients with similar progressive lesions. In general, the higher levels of IL-10 than of TNFα suggested a potential down-modulation of tumor-specific immune responses to HPV-infected lesions. This phenomenon appears to provide a tumor 'progressive' microenvironment in these particular patients.
本研究旨在评估 HPV DNA⁺和 DNA⁻宫颈病变女性的免疫反应。纳入了 80 名宫颈病变患者（年龄 25-70 岁）和 20 名健康个体（对照组）。在 HPV DNA 检测之前，细胞学将病变分为四组：ASC-US（20 例）、CINI（30 例）、CINII-III（16 例）和宫颈癌（14 例）。利用 ELISA 测定宫颈分泌物和血清中白细胞介素（IL）-10 和肿瘤坏死因子（TNF）-α水平。利用 PCR 筛查试剂盒检测宫颈拭子中的 HPV DNA，这些病例具有不同的病变。HPV DNA⁺宫颈分泌物中的 IL-10 水平明显高于 HPV DNA⁻患者（即 88.73 比 24.00 pg/ml）和对照组（即 88.73 比 8.27 pg/ml），且 DNA⁻患者高于对照组（即 24.00 比 8.27 pg/ml）。相比之下，这些患者的血清 IL-10 水平与对照组无显著差异（即分别为 13.69、12.16 和 9.99 pg/ml）。HPV DNA⁺和 DNA⁻病例宫颈分泌物中的 TNFα 水平与对照组无显著差异（即分别为 12.18、9.90 和 7.90 pg/ml）。这些患者的血清 TNFα 与对照组也无显著差异（即分别为 11.59、11.90 和 10.83 pg/ml）。HPV DNA⁺病变患者宫颈分泌物中检测到的 IL-10 水平明显高于血清，而分泌型 TNFα 水平略高于血清值。最后，在 10-14 例（71.4%）进展性宫颈病变（HSIL 和宫颈癌阶段）HPV DNA⁺患者的分泌物中观察到较高水平的 IL-10，而在 66 例（30.0%）具有相似进展性病变的 DNA⁻患者的 20 例中观察到较高水平的 IL-10。一般来说，IL-10 水平高于 TNFα 表明 HPV 感染病变的肿瘤特异性免疫反应可能受到抑制。这种现象似乎为这些特定患者提供了一个肿瘤“进展”的微环境。
